Emerging application of nanomedicine-based therapy in acute respiratory distress syndrome
Copyright © 2024 Elsevier B.V. All rights reserved..
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are serious lung injuries caused by various factors, leading to increased permeability of the alveolar-capillary barrier, reduced stability of the alveoli, inflammatory response, and hypoxemia. Despite several decades of research since ARDS was first formally described in 1967, reliable clinical treatment options are still lacking. Currently, supportive therapy and mechanical ventilation are prioritized, and there is no medication that can be completely effective in clinical treatment. In recent years, nanomedicine has developed rapidly and has exciting preclinical treatment capabilities. Using a drug delivery system based on nanobiotechnology, local drugs can be continuously released in lung tissue at therapeutic levels, reducing the frequency of administration and improving patient compliance. Furthermore, this novel drug delivery system can target specific sites and reduce systemic side effects. Currently, many nanomedicine treatment options for ARDS have demonstrated efficacy. This review briefly introduces the pathophysiology of ARDS, discusses various research progress on using nanomedicine to treat ARDS, and anticipates future developments in related fields.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:237 |
|---|---|
| Enthalten in: |
Colloids and surfaces. B, Biointerfaces - 237(2024) vom: 05. Apr., Seite 113869 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Yitianhe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute lung injury |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.colsurfb.2024.113869 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370118529 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370118529 | ||
| 003 | DE-627 | ||
| 005 | 20240408232828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.colsurfb.2024.113869 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM370118529 | ||
| 035 | |a (NLM)38522285 | ||
| 035 | |a (PII)S0927-7765(24)00127-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Yitianhe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging application of nanomedicine-based therapy in acute respiratory distress syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are serious lung injuries caused by various factors, leading to increased permeability of the alveolar-capillary barrier, reduced stability of the alveoli, inflammatory response, and hypoxemia. Despite several decades of research since ARDS was first formally described in 1967, reliable clinical treatment options are still lacking. Currently, supportive therapy and mechanical ventilation are prioritized, and there is no medication that can be completely effective in clinical treatment. In recent years, nanomedicine has developed rapidly and has exciting preclinical treatment capabilities. Using a drug delivery system based on nanobiotechnology, local drugs can be continuously released in lung tissue at therapeutic levels, reducing the frequency of administration and improving patient compliance. Furthermore, this novel drug delivery system can target specific sites and reduce systemic side effects. Currently, many nanomedicine treatment options for ARDS have demonstrated efficacy. This review briefly introduces the pathophysiology of ARDS, discusses various research progress on using nanomedicine to treat ARDS, and anticipates future developments in related fields | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Acute lung injury | |
| 650 | 4 | |a Acute respiratory distress syndrome | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a Nanomedicine | |
| 650 | 4 | |a Precision therapy | |
| 700 | 1 | |a Lv, Leyao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Kou, Longfa |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hailin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Colloids and surfaces. B, Biointerfaces |d 1994 |g 237(2024) vom: 05. Apr., Seite 113869 |w (DE-627)NLM09266623X |x 1873-4367 |7 nnns |
| 773 | 1 | 8 | |g volume:237 |g year:2024 |g day:05 |g month:04 |g pages:113869 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.colsurfb.2024.113869 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 237 |j 2024 |b 05 |c 04 |h 113869 | ||